Efficacy and Safety of an Ectoine-containing Cream in the Treatment of Mild to Moderate Atopic Dermatitis

Exclusion Criteria

• •Patients who are self-reported to be pregnant, nursing or planning pregnancy during the clinical investigation
• •Patients with any skin disease that in the investigator's opinion may interfere with the conduct of the study or the evaluation of the results (e.g. psoriasis)
• •Patients with a known malignancy
• •Presence of any disease and/or condition and/or history of diseases and/or conditions that according to the investigator may interfere with the conduct of the investigation or the evaluation of the results (such as abnormal laboratory values, chronic inflammatory dis-eases, immunosuppressive diseases, autoimmune diseases, liver or kidney diseases, severe infectious diseases)
• •Patients who did not respect the wash-out periods prior to and during the clinical investigation
• •Vaccination within 6 days prior to enrolment and during the study.
• •Patients with a known allergy against any ingredient of the test products
• •Patients who are known to have had a substance abuse (drug or alcohol) problem within the previous 12 months
• •Patients who participate in another clinical trial or have participated in another clinical trial within the last 30 days prior to the first day of investigation
• •Patients who are involved in the organization of the clinical investigation
• •Patients that are in any way dependant on the investigator